Phase-III trial of indigenous one-shot dengue vaccine by Panacea Biotec shows promising results in India, aiming for ...

The one-shot vaccine, developed by Panacea Biotec and branded as DengiAll, is being tested through a multi-centre, ...

The vaccine strain (TV003/TV005), originally developed by the US National Institutes of Health (NIH), has shown promising results in global studies ...

The new vaccine aims to provide protection against all four dengue serotypes. Read more at straitstimes.com. Read more at ...

Merck, known as MSD outside of the United States and Canada, today announced the initiation of the MOBILIZE-1 Phase 3 clinical trial evaluating the safety, immunogenicity and efficacy of a single ...

WHO’s new global guidance helps clinicians manage dengue, Zika, chikungunya, and yellow fever with protocols for fluids, ...

For years now, scientists have tried to develop a safe and effective dengue vaccine. The challenge however, is that there are four different types of dengue viruses, and a common vaccine must protect ...

After recovering from dengue fever, there are times when you experience prolonged fatigue, joint pain, hair loss, along with reduced immunity. These post-recovery symptoms can complicate the return to ...

Teams from various departments have sprung into action to prevent and control vector-borne diseases like dengue, malaria, and ...

SII partners with DNDi to develop affordable dengue treatment, aiming to save lives in LMICs and endemic countries.

Enrolment of about 10,500 participants in the phase III clinical trial of the indigenous one-shot Panacea Biotec developed ...